Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie-Paule Sablin

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Endocrinology and Metabolism Clinics of North America|November 25, 2010
Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumorsSandrine Faivre, Marie-Paule Sablin, Chantal Dreyer, et al.
Therapie|June 22, 2007
[Irinotecan and liver dysfunctions]Marie-Paule Sablin, Christophe Le Tourneau, Sandrine Faivre, et al.
La Revue Du Praticien|January 5, 2011
[Targeted therapies in colorectal cancer]Marie-Paule Sablin, Chantal Dreyer, Camélia Colichi, et al.
Bulletin Du Cancer|July 12, 2011
[PI3K-AKT-mTOR pathway and cancer]Laetitia Coutte, Chantal Dreyer, Marie-Paule Sablin, et al.
Expert Opinion on Investigational Drugs|June 24, 2010
New inhibitors of the mammalian target of rapamycin signaling pathway for cancerSébastien Albert, Maria Serova, Chantal Dreyer, et al.
Bulletin Du Cancer|September 13, 2007
[Gemcitabine and pemetrexed: novel associations and mechanisms of resistance]Marie-Paule Sablin, Christophe Le Tourneau, Ghassan El Maalouf, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|March 13, 2020
CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neckCamelia Billard-Sandu, Yun-Gan Tao, Marie-Paule Sablin, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 20, 2010
Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical developmentMarie-Paule Sablin, Chantal Dreyer, Camelia Colichi, et al.
Targeted Oncology|May 3, 2011
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitorsCatherine Delbaldo, Sébastien Albert, Chantal Dreyer, et al.
Chinese Clinical Oncology|April 6, 2015
The spectrum of clinical trials aiming at personalizing medicineChristophe Le Tourneau, Maud Kamal, Marie Alt, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Endocrinology and Metabolism Clinics of North America|November 25, 2010
Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumorsSandrine Faivre, Marie-Paule Sablin, Chantal Dreyer, et al.
Therapie|June 22, 2007
[Irinotecan and liver dysfunctions]Marie-Paule Sablin, Christophe Le Tourneau, Sandrine Faivre, et al.
La Revue Du Praticien|January 5, 2011
[Targeted therapies in colorectal cancer]Marie-Paule Sablin, Chantal Dreyer, Camélia Colichi, et al.
Bulletin Du Cancer|July 12, 2011
[PI3K-AKT-mTOR pathway and cancer]Laetitia Coutte, Chantal Dreyer, Marie-Paule Sablin, et al.
Expert Opinion on Investigational Drugs|June 24, 2010
New inhibitors of the mammalian target of rapamycin signaling pathway for cancerSébastien Albert, Maria Serova, Chantal Dreyer, et al.
Bulletin Du Cancer|September 13, 2007
[Gemcitabine and pemetrexed: novel associations and mechanisms of resistance]Marie-Paule Sablin, Christophe Le Tourneau, Ghassan El Maalouf, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|March 13, 2020
CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neckCamelia Billard-Sandu, Yun-Gan Tao, Marie-Paule Sablin, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 20, 2010
Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical developmentMarie-Paule Sablin, Chantal Dreyer, Camelia Colichi, et al.
Targeted Oncology|May 3, 2011
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitorsCatherine Delbaldo, Sébastien Albert, Chantal Dreyer, et al.
Chinese Clinical Oncology|April 6, 2015
The spectrum of clinical trials aiming at personalizing medicineChristophe Le Tourneau, Maud Kamal, Marie Alt, et al.
Pageof 6